FDA Conditionally Accepts Acurx's CIFBEZY Brand Name for Ibezapolstat
ACXP is trading near its 52-week low of $1.31 (3.8% above the low) on elevated volume (5.9× avg).
Summary
Acurx secured FDA conditional acceptance and USPTO trademark allowance for CIFBEZY, the brand name for its lead antibiotic ibezapolstat. This is a regulatory milestone that de-risks the commercial path for the drug, which is Phase 3 ready for C. difficile infection. The company is trading near its 52-week low with a market cap around $7.4 million and a going concern warning, so this news provides a modest positive signal but does not address the financing gap. The brand name approval is contingent on NDA approval, and final FDA review will occur at marketing application. This follows the August 3 FDA meeting minutes that outlined a streamlined approval path, reinforcing the regulatory momentum.
At the time of this announcement, ACXP was trading at $1.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.4M. The 52-week trading range was $1.31 to $8.34. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.